Literature DB >> 9290298

Pharmacological management of post-traumatic stress disorder: clinical summary of a five-year retrospective study, 1990-1995.

J Viola1, T Ditzler, W Batzer, J Harazin, D Adams, L Lettich, T Berigan.   

Abstract

Beginning in 1990, the Department of Psychiatry. Tripler Army Medical Center developed a formal treatment program for post-traumatic stress disorder (PTSD). Between 1990 and 1996, 632 patients, the vast majority of whom suffered from combat-related PTSD, were treated. Historically, many PTSD patients were treated with benzodiazepines, often in high dosages. The risks attendant to benzodiazepine management of PTSD, coupled with poor clinical outcome, prompted the staff to explore treatment alternatives. This paper describes the role of pharmacotherapy in the management of PTSD. The medications described in this paper have other primary uses in clinical practice (e.g., hypertension, insomnia, seizure control, depression, and anxiety). Medications were selected for use based on the putative modes of action and the degree of symptom relief. The therapeutic rationale was to decrease hyperarousal and sleep disturbance to permit the patients to engage in other psychotherapeutic efforts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9290298

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  13 in total

Review 1.  Antiepileptic drugs for the treatment of post-traumatic stress disorder.

Authors:  Heather A Berlin
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

2.  Preclinical evaluation of reconsolidation blockade by clonidine as a potential novel treatment for posttraumatic stress disorder.

Authors:  Karine Gamache; Roger K Pitman; Karim Nader
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

Review 3.  Post-traumatic stress disorder and cancer.

Authors:  Matthew J Cordova; Michelle B Riba; David Spiegel
Journal:  Lancet Psychiatry       Date:  2017-01-19       Impact factor: 27.083

Review 4.  Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder.

Authors:  Graziano Pinna; Ann M Rasmusson
Journal:  J Neuroendocrinol       Date:  2012-01       Impact factor: 3.627

5.  5α-reductase type I expression is downregulated in the prefrontal cortex/Brodmann's area 9 (BA9) of depressed patients.

Authors:  Roberto Carlos Agis-Balboa; Alessandro Guidotti; Graziano Pinna
Journal:  Psychopharmacology (Berl)       Date:  2014-04-30       Impact factor: 4.530

Review 6.  In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis.

Authors:  Graziano Pinna
Journal:  Behav Pharmacol       Date:  2010-09       Impact factor: 2.293

7.  Enhancing Completion of Cognitive Processing Therapy for Posttraumatic Stress Disorder with Quetiapine in Veterans with Mild Traumatic Brain Injury: a Case Series.

Authors:  Muhammad R Baig; Jennifer L Wilson; Jennifer A Lemmer; Robert D Beck; Alan L Peterson; John D Roache
Journal:  Psychiatr Q       Date:  2019-06

8.  Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: A model relevant for posttraumatic stress disorder.

Authors:  Fabio Pibiri; Marianela Nelson; Alessandro Guidotti; Erminio Costa; Graziano Pinna
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

9.  Neurosteroids reduce social isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated upregulation of BDNF expression.

Authors:  Mauricio Schüler Nin; Luis A Martinez; Fabio Pibiri; Marianela Nelson; Graziano Pinna
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-21       Impact factor: 5.555

Review 10.  Post-traumatic stress disorder: revisiting adrenergics, glucocorticoids, immune system effects and homeostasis.

Authors:  Gerald D Griffin; Dominique Charron; Rheem Al-Daccak
Journal:  Clin Transl Immunology       Date:  2014-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.